NCT00999830 · FLOW

Participant flow

Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple Myeloma · Source last updated 2016-03-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

description
IPH2101 Fully human anti-KIR monoclonal antibody : 0.2mg/Kg , every 4 weeks by intravenous route over 1 hour, for 4 cycles. Patients responding at 4 months will be allowed to receive an additional period of treatment of 4 monthly.
id
FG000
title
Arm A: IPH2101 0.2mg/Kg
description
IPH2101 Fully human anti-KIR monoclonal antibody : 2mg/Kg , every 4 weeks by intravenous route over 1 hour, for 4 cycles. Patients responding at 4 months will be allowed to receive an additional period of treatment of 4 monthly.
id
FG001
title
Arm B: IPH2101 2mg/kg

periods

milestones
achievements
group Id
FG000
num Subjects
14
group Id
FG001
num Subjects
13
type
STARTED
achievements
group Id
FG000
num Subjects
14
group Id
FG001
num Subjects
13
type
COMPLETED
achievements
group Id
FG000
num Subjects
0
group Id
FG001
num Subjects
0
type
NOT COMPLETED
title
Overall Study

pre Assignment Details

All patients enrolled in the study were analyzed. There was no screen failure during the trial conduct.

recruitment Details

Patients were recruited in France at the public hospital (10 actives center), from mid of November 2009 to end of October 2011.

Complete source fields